Ginkgo Bioworks Holdings, Inc. revenue by segment DNA

Annual Quarterly

Ginkgo Bioworks Holdings, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Cell Engineering Revenue at $132.7 million, 78% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
132
170
227
251
478
314
Cell Engineering Revenue
—
133
-23.7%
share 78.0%
174
+21.2%
share 76.6%
144
-0.1%
share 57.1%
144
+27.2%
share 30.1%
113
share 36.0%
Services
—
37
-29.5%
share 22.0%
53
-32.8%
share 23.4%
79
-73.6%
share 31.4%
299
+67.9%
share 62.5%
178
share 56.7%
Product
—
—
—
29
-18.4%
share 11.5%
35
+53.9%
share 7.4%
23
share 7.3%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
DNA (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Accelerated filer
SEC CIK
1830214
Former names
Soaring Eagle Acquisition Corp. (until Sep 17, 2021); Spinning Eagle Acquisition Corp. (until Jan 4, 2021)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.